Corticosteroids for treating nerve damage in leprosy. A Cochrane review

Leprosy Review

Volumn 79, Issue 4, 2008, Pages 361-371

  Van Veen, Natasja H J ^a   Nicholls, Peter G ^b   Smith, W Cairns S ^c   Richardus, Jan Hendrik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; PREDNISOLONE; GLUCOCORTICOID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; LEPROSY; LOW DRUG DOSE; NERVE FUNCTION; NERVE INJURY; OUTCOME ASSESSMENT; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; PERIPHERAL NEUROPATHY; SOMATOSENSORY DISORDER; TREATMENT OUTCOME;

GLUCOCORTICOIDS; HUMANS; LEPROSY; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOSENSORY DISORDERS; TREATMENT OUTCOME;

EID: 63049108668     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Lepr Rev, 2000; 71(Suppl): S111-S114.
2. Britton WJ. The management of leprosy reversal reactions. Lepr Rev, 1998; 69: 225-234.
3. Becx-Bleumink M, Berhe D, Mannetje W. The management of nerve damage in the leprosy control services. Lepr Rev, 1990; 61: 1-11.
4. Naafs B. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis, 1996; 64: S21-S28.
5. WHO Action Programme for the Elimination of Leprosy. A guide to eliminate leprosy as a public health problem. 1995.
6. Little D, Khanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular in ltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun, 2001; 69: 3413-3417.
7. Naafs B, Pearson JM, Wheate HW. Reversal reaction: the prevention of permanent nerve damage. Comparison of short and longterm steroid treatment. Int J Lepr Other Mycobact Dis, 1979; 47: 7-12.
8. Naafs B. Treatment duration of reversal reaction: a reappraisal. Back to the past. Lepr Rev, 2003; 74: 328-336.
9. World Health Organization. WHO Expert Committee on Leprosy. WHO Technical Report Series 1998; 874: 1-43.
10. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Lepr Rev, 2003; 74: 319-327.
11. Sugumaran DS. Leprosy reactions-complications of steroid therapy. Int J Lepr Other Mycobact Dis, 1998; 66: 10-15.
12. Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
13. Lockwood DN, Vinayakumar S, Stanley JN et al. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis, 1993; 61: 8-15.
14. Saunderson P, Gebre S, Desta K et al. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev, 2000; 71: 285-308.
15. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments. Int J Lepr Other Mycobact Dis, 1998; 66: 170-181.
16. Boucher P, Millan J, Parent M, Moulia-Pela JP. [Randomized controlled trial of medical and medico-surgical treatment of Hansen's neuritis] Essai compare randomise du traitement medical et medico-chirurgical des nevrites hanseniennes. Acta Leprol, 1999; 11: 171-177.
17. Ebenezer M, Andrews P, Solomon S. Comparative trial of steroids and surgical intervention in the management of ulnar neuritis. Int J Lepr Other Mycobact Dis, 1996; 64: 282-286.
18. Pannikar VK, Ramprasad S, Reddy NR et al. Effect of epicondylectomy in early ulnar neuritis treated with steroids. Int J Lepr Other Mycobact Dis, 1984; 52: 501-505.
19. Marlowe SN, Hawksworth RA, Butlin CR et al. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg, 2004; 98: 602-609.
20. Marlowe SN, Leekassa R, Bizuneh E et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg, 2007; 101: 1004-1012.
21. Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 1999; 70: 140-159.
22. van Brakel WH, Nicholls PG, Das L et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev, 2005; 76: 14-34.
23. Brandsma W. Basic nerve function assessment in leprosy patients. Lepr Rev, 1981; 52: 161-170.
24. Van Brakel WH, Anderson AM, Withington SG et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003; 74: 300-310.
25. Richardus JH, Withington SG, Anderson AM et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003; 74: 311-318.
26. Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev, 2006; 77: 25-33.
27. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: an epidemiological and clinical study-Part 2: Results of steroid treatment. Lepr Rev,1996; 67: 104-118.
28. Pearson JM. The use of corticosteroids in leprosy. Lepr Rev, 1981; 52: 293-298.
29. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev, 1991; 62: 113-121.
30. Smith WC, Anderson AM, Withington SG. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ, 2004; 328(7454): 1459.